The role of microRNA in head and neck cancer: Current knowledge and perspectives

Molecules

Volumn 19, Issue 5, 2014, Pages 5704-5716

  Courthod, Giulia ^a   Franco, Pierfrancesco ^a   Palermo, Loredana ^b   Pisconti, Salvatore ^c   Numico, Gianmauro ^a  

^a Medical Physics Department   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

Author keywords

Biomarkers; Chemoresistence; Hand and neck cancer; MicroRNA; Radioresistence

Indexed keywords

MICRORNA; TUMOR MARKER;

CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS;

CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901477202     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19055704     Document Type: Review

References (58)

1. Ferlay J.; Steliarova-Foucher E.; Lortet-Tieulent J.; Rosso S.; Coebergh J.W.; Comber H.; Forman D.; Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49, 1374-1403.
2. Perez-Ordonez B.; Beauchemin M.; Jordan R.C. Molecular biology of squamous cell carcinoma of the head and neck. J. Clin. Pathol. 2006, 59, 445-453.
3. Bonner J.A.; Harari P.M.; Giralt J.; Cohen R.B.; Jones C.U.; Sur R.K.; Raben D.; Baselga J.; Spencer S.A.; Zhu J.; et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11, 21-28.
4. Vermorken J.B.; Mesia R.; Rivera F.; Remenar E.; Kawwecki A.; Rottey S.; Erfan J.; Zabolotnyy D.; Kienzer H.; Cupissol D.; et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N. Engl. J. Med. 2008, 359, 1116-1127.
5. Numico G.; Franco P.; Cristofano A.; Migliaccio F.; Spinazzé S.; Silvestris N.; Cante D.; Sciacero P.; la Porta M.R.; Girelli F.; et al. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit. Rev. Oncol./Hematol. 2013, 85, 112-120.
6. Numico G.; Silvestris N.; Grazioso Russi N. Advances in EGFR-directed therapy in head and neck cancer. Front. Biosci. 2011, 3, 454-466.
7. Leemans C.R.; Braakhuis B.J.M.; Brakenhoff R.H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011, 11, 9-22.
8. Homo Sapiens miRNA (1872 Sequences). Available online: http://www.mirbase.org/cgibin/mirna-summary.pl?org=hsa (accessed on 21 March 2014).
9. Lee Y.; Kim M.; Han J.; Yeom K.H.; Lee S.; Baek S.H.; Kim V.N. microRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23, 4051-4060.
10. Cai X.; Hagedorn C.H.; Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10, 1957-1966.
11. Kwak P.B.; Iwasaki S.; Tomari Y. The microRNA pathway and cancer. Cancer Sci. 2010, 101, 2309-2315.
12. Garzon R.; Calin G.A.; Croce C.M. microRNAs in cancer. Annu. Rev. Med. 2009, 60, 167-179.
13. Hu Z.; Chen X.; Zhao Y.; Tian T.; Jin G.; Shu Y.; Chen Y.; Xu L.; Zen K.; Zhang C.; et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small cell lung cancer. J. Clin. Oncol. 2010, 28, 1721-1726.
14. Van Rooij E.; Purcell A.L.; Levin A.A. Developing microRNA therapeutics. Circ. Res. 2012, 110, 496-507.
15. Costinean S.; Zanesi N.; Pekarsky Y.; Till E.; Volinia S.; Heerema N.; Croce C.M. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice. Proc. Natl. Acad. Sci. USA 2006, 103, 7024-7029.
16. Avissar M.; Christensen B.C.; Kelsey K.T.; Marsit C.J. microRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin. Cancer Res. 2009, 15, 2850-2855.
17. Barker E.V.; Cervigne N.K.; Reis P.P.; Goswami R.S.; Xu W.; Weinreb I.; Irish J.C.; Kamel-Reis S. microRNA evaluation of unknown primary lesions in the head and neck. Mol. Cancer 2009, 8, 127.
18. Cao P.; Zhou L.; Zhang J.; Zheng F.; Wang H.; Ma D.; Tian J. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck 2013, 35, 720-728.
19. Cervigne N.K.; Reis P.P.; Machado J.; Sadikovic B.; Bradley G.; Galloni N.N.; Pintilie M.; Jurisica I.; Perez-Ordonez B.; Gilbert P.; et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum. Mol. Genet. 2009, 18, 4818-4829.
20. Chang S.S.; Jiang W.W.; Smith I.; Poeta L.M.; Begum S.; Glazer C.; Shan S.; Westra W.; Sidransky D.; Califano J.A. microRNA alterations in head and neck squamous cell carcinoma. Int. J. Cancer 2008, 123, 2791-2797.
21. Childs G.; Fazzari M.; Kung G.; Kawachi N.; Brandwein-Gensler M.; McLemore M.; Chen Q.; Burk R.D.; Smith R.V.; Prystowsky M.B.; et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 2009, 174, 736-745.
22. Christensen B.C.; Moyer B.J.; Avissar M.; Ouellet L.G.; Plaza S.L.; McClean M.D.; Marsit C.J.; Kelsey K.T. A let-7 microRNA-binding site polymorphism in the KRAS 30 UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009, 30, 1003-1007.
23. Fletcher A.M.; Heaford A.C.; Trask D.K. Detection of metastatichead and neck squamous cell carcinoma using the relative expres-sion of tissue-specific miR-205. Transl. Oncol. 2008, 1, 202-208.
24. Hui A.B.Y.; Lenarduzzi M.; Krushel T.; Waldron L.; Pintilie M.; Shi W.; Perez-Ordonez B.; Jurisica I.; O'sullivan B.; Waldrom J.; et al. Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin. Cancer Res. 2009, 16, 1129-1139.
25. Kozaki K.; Imoto I.; Mogi S.; Omura K.; Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylationin oral cancer. Cancer Res. 2008, 68, 2094-2105.
26. Lajer C.B.; Nielsen F.C.; Friis-Hansen L.; Norrild B.; Borup R.; Garnaes E.; Rossing M.; Specht L.; Therkildsen M.H.; Nauntofte B.; et al. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: A prospective translational study. Br. J. Cancer 2011, 104, 830-840.
27. Li J.; Huang H.; Sun L.; Yang M.; Pan C.; Chen W.; Wu D.; Lin Z.; Zeng C.; Yao Y.; et al. miR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res. 2009, 15, 3998-4008.
28. Liu C.J.; Tsai M.M.; Hung P.S.; Kao S.Y.; Liu T.Y.; Wu K.J.; Chiou S.H.; Lin S.C.; Chang K.W. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010, 70, 1635-1644.
29. Kikkawa N.; Hanazawa T.; Fujimura L.; Nohata N.; Suzuki H.; Chazono H.; Sakurai D.; Horiguchi S.; Okamoto Y.; Seki N. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br. J. Cancer 2010, 103, 877-884.
30. Nohata N.; Hanazawa T.; Kikkawa N.; Sakurai D.; Fujimura L.; Chiyomaru T.; Kawakami K.; Yoshino H.; Enokida H.; Nakagawa M.; et al. Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br. J. Cancer 2011, 105, 833-841.
31. Ramdas L.; Giri U.; Ashorn C.L.; Coombes K.R.; El-Naggar A.; Ang K.K.; Story M.D. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 2009, 31, 642-654.
32. Rentoft M.; Fahlen J.; Coates P.J.; Laurell G.; Sjostrom B.; Ryden P.; Nylander K. miRNA analysis of formalin-fixed squamous cell carcinoma of the tongue is affected by age of the sample. Int. J. Oncol. 2011, 38, 61-69.
33. Scapoli L.; Palmieri A.; Lo Muzio L.; Pezzetti F.; Rubini C.; Girardi A.; Farinella F.; Mazzotta M.; Carinci F. microRNA expression profiling of oral carcinoma identifies new markers of tumor progressione. Int. J. Immunopathol. Pharmacol. 2010, 23, 1229-1234.
34. Tran M.; McLean T.; Zhang X.; Zhao C.J.; Thomson J.M.; O'Brien C.; Rose B. microRNA expression profiles in head and neck cancer cell lines. Biochem. Biophys. Res. Commun. 2007, 358, 12-17.
35. Wiklund E.D.; Gao S.; Hulf T.; Sibbritt T.; Shalima N.; Costea D.E.; Villadsen S.B.; Bakholdt V.; Bramsen J.B.; Sørensen J.A.; et al. microRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One 2011, 6, e27840.
36. Wong T.S.; Liu X.B.; Wong B.Y.; Ng R.W.; Yuen A.P.; Wei W.I. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res. 2008, 14, 2588-2592.
37. Xiao W.; Bao Z.X.; Zhang C.Y.; Zhang X.Y.; Shi L.J.; Zhou Z.T.; Jiang W.W. Upregulation of miR-31 is negatively associated with recurrent/newly formed oral leukoplakia. PLoS One 2012, 7, e38648.
38. Meng F.; Henson R.; Wehbe-Janek H.; Ghoshal K.; Jacob S.T.; Patel T. microRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133, 647-658.
39. Frankel L.B.; Christoffersen N.R.; Jacobsen A.; Lindow M.; Krogh A.; Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283, 1026-1033.
40. Darido C.; Georgy S.R.; Wilanowski T.; Dworkin S.; Auden A.; Zhao Q.; Rank G.; Srivastava S.; Finlay M.J.; Papenfuss A.T.; et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell 2011, 20, 635-648.
41. Wong T.S.; Man O.Y.; Tsang C.M.; Tsao S.W.; Tsang R.K.; Chang J.Y.; Ho W.K.; Wei W.I.; To V.S. microRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J. Cancer Res. Clin. Oncol. 2011, 137, 415-422.
42. Chin L.J.; Ratner E.; Leng S.G.; Zhai R.H.; Nallur S.; Babar I.; Muller R.U.; Starka E.; Su L.; Burki E.A.; et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untraslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68, 8535-8540.
43. Poeta M.L.; Manola J.; Goldwasser M.A.; Forastiere A.; Benoit N.; Califano J.A.; Ridge J.A.; Goodwi J.; Kenady D.; Saunders J.; et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2007, 357, 2552-2561.
44. Ganci F.; Sacconi A.; Bossel Ben-Moshe N.; Manciocco V.; Sperduti I.; Strigari L.; Covello R.; Benevolo M.; Pescarmona E.; Domany E.; et al. Expression of TP53 mutation-Associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann. Oncol. 2013, 24, 3082-3088.
45. Harris T.; Jimenez L.; Kawachi N.; Fan J.; Chen J.; Belbin T.; Ramnauth A.; Loudig O.; Keller C.E.; Smith R.; et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am. J. Pathol. 2012, 180, 917-928.
46. Gee H.E.; Camps C.; Buffa F.M.; Patiar S.; Winter S.C.; Betts G.; Homer J.; Corbridge R.; Cox G.; West C.M.; et al. Has-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010, 116, 2148-2158.
47. Park N.J.; Zhou H.; Elashoff D.; Henson B.S.; Kastratovic D.A.; Abemayor E.; Wong D.T. Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 2009, 15, 5473-5477.
48. Liu C.J.; Lin S.C.; Yang C.C.; Cheng H.W.; Chang K.W. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 2012, 34, 219-224.
49. Liu C.J.; Kao S.Y.; Tu H.F.; Tsai M.M.; Chang K.W.; Lin S.C. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010, 16, 360-364.
50. Clague J.; Lippman S.M.; Yang H.; Hildebrandt M.A.; Ye Y.; Lee J.J.; Wu X. Genetic variation in microRNA genes and risk of oral premalignant lesions. Mol. Carcinog. 2010, 49, 183-189.
51. Yu Z.; Zhong L.; Zhang P.; Chen W.; Zhang C. microRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 2010, 46, 317-322.
52. Meng F.; Henson R.; Lang M.; Wehbe H.; Maheshwari S.; Mendell J.T.; Jiang J.; Schmittgen T.D.; Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130, 2113-2129.
53. Yang H.; Kong W.; He L.; Zhao J.J.; O'Donnell J.D.; Wang J.; Weham R.M.; Coppola D.; Kruk P.A.; Nicosia S.V.; et al. microRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68, 425-433.
54. Niemoeller O.M.; Niyazi M.; Corradini S.; Zehentmayr F.; Li M.; Lauber K.; Belka C. microRNA expression profiles in human cancer cells after ionizing radiation. Radiat. Oncol. 2011, 6, 29.
55. Qu C.; Liang Z.; Huang J.; Zhao R.; Su C.; Wang S.; Wang X.; Zhang R.; Lee M.; Yang H. miR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle 2012, 11, 785-796.
56. Shiiba M.; Shinozuka K.; Saito K.; Fushimi K.; Kasamatsu A.; Ogawara K.; Uzawa K.; Ito H.; Takiguchi Y.; Tanzawa H. microRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma. Br. J. Cancer 2013, 108, 1817-1821.
57. Janssen H.L.A.; Reesink H.W.; Lawitz E.J.; Zeuzem S.; Rodriquez-Torres M.; Patel K.; van der Meer A.; Patick A.K.; Chena A.; Zhou Y. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368, 1685-1694.
58. Mirna Therapeutics, Inc. A Multicenter Phase I Study of MRX34, microRNA miR-RX34 Liposome Injectable Suspension. U.S. National Institutes of Health, October 2013. Available online: http://www.clinicaltrials.gov/ct2/show/ NCT01829971 (accessed on 30 April 2014).